Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $429.00 at Canaccord Genuity Group

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target boosted by Canaccord Genuity Group from $415.00 to $429.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research firms also recently commented on ALNY. Piper Sandler reaffirmed an “overweight” rating and set a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Chardan Capital reduced their price target on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Truist Financial decreased their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Needham & Company LLC dropped their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Finally, Leerink Partners cut their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. Twenty-two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Trading Up 5.8%

NASDAQ:ALNY opened at $332.61 on Tuesday. The company has a market capitalization of $44.11 billion, a P/E ratio of 194.51 and a beta of 0.35. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $495.55. The firm has a fifty day simple moving average of $371.01 and a 200-day simple moving average of $424.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same period in the previous year, the company earned ($0.65) earnings per share. Alnylam Pharmaceuticals’s revenue was up 84.9% on a year-over-year basis. On average, equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 9,577 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.86, for a total value of $3,475,110.22. Following the transaction, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. This trade represents a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Tolga Tanguler sold 1,959 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the completion of the sale, the executive vice president directly owned 31,769 shares in the company, valued at $9,850,931.52. This represents a 5.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,578 shares of company stock worth $12,416,105 in the last three months. 1.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Thematics Asset Management purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at $1,995,000. Mediolanum International Funds Ltd acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at $11,389,000. Teacher Retirement System of Texas increased its stake in Alnylam Pharmaceuticals by 3.2% in the second quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock valued at $11,872,000 after purchasing an additional 1,123 shares during the period. Rakuten Investment Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $14,205,000. Finally, Generali Asset Management SPA SGR boosted its stake in shares of Alnylam Pharmaceuticals by 6,368.0% during the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after buying an additional 3,184 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and reaffirmed a “buy” rating, citing upside vs. the current price (Canaccord’s note implies meaningful upside). Canaccord price-target raise
• Positive Sentiment: A MarketBeat-linked Motley Fool piece reports a pundit upgrade that helped lift sentiment and trading interest in ALNY. Why Alnylam Was Soaring
• Positive Sentiment: A bullish roundup in The Globe and Mail highlighted Alnylam among favorable healthcare ideas, supporting broader analyst-driven positivity. Analysts Are Bullish
• Neutral Sentiment: Short-interest data in the feed shows zero/NaN values and a 0.0 days-to-cover figure — likely a data/reporting artifact rather than new market pressure; treat as non-actionable until confirmed by an exchange report.
• Negative Sentiment: Multiple insider sales disclosed this week could weigh on sentiment: CEO Yvonne Greenstreet sold 6,958 shares at ~$310; several EVPs (Jeffrey Poulton, Kevin Fitzgerald, Tolga Tanguler, Pushkal Garg) sold mid‑hundreds to low‑thousands of shares at ~$310–332. These trades reduced insiders’ stakes by mid-single-digit percentages. Filings: SEC links for the disclosures. Yvonne Greenstreet SEC filing Jeffrey Poulton SEC filing Kevin Fitzgerald filings Tolga Tanguler SEC filing Pushkal Garg SEC filing
• Negative Sentiment: Chardan Capital trimmed its price target to $425 (from a higher prior target), a modest negative datapoint that partly offsets other analyst optimism. Chardan target cut

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.